Phosphodiesterase 4 inhibitors for the treatment of asthma

By Karlsson J-A.   Aldous D.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 9, 1997-09 ,pp. : 989-1003

Informa Healthcare

Access to resources Recommend Favorite

Ariflo^TM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic

By Torphy T.J.   Barnette M.S.   Underwood D.C.   Griswold D.E.   Christensen S.B.   Murdoch R.D.   Nieman R.B.   Compton C.H.  

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 2, 1999-04 ,pp. : 131-135

Academic Press

Access to resources Recommend Favorite

Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions

By  

Current Medicinal Chemistry, Vol. 23, Iss. 2, 2016-01 ,pp. : 129-141

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies

By Dal Piaz V.   Giovannoni M.P.  

European Journal of Medicinal Chemistry, Vol. 35, Iss. 5, 2000-05 ,pp. : 463-480

Elsevier

Access to resources Recommend Favorite

Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease

By Spina D.  

Drugs, Vol. 63, Iss. 23, 2003-01 ,pp. : 2575-2594

Adis International

Access to resources Recommend Favorite